Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENEFLUID intradialytic parenteral nutrition in malnourished maintenance hemodialysis patients
jRCTs031220296Completed
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of Enefluid in chronic kidney disease (CKD) and protein-calorie malnutrition (PCM) (2 arms), sponsored by Otsuka Pharmaceutical Factory, Inc. Primary endpoint: serum transthyretin levels. Started Sep 2022; status: completed.
02
Drugs
Enefluid
03
Conditions
chronic kidney disease (CKD)protein-calorie malnutrition (PCM)
Beyond the preview
Go deeper on jRCTs031220296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220296.